Published in Neural Plast on January 09, 2017
The Link between Depression and Chronic Pain: Neural Mechanisms in the Brain. Neural Plast (2017) 0.75
Biological insights from 108 schizophrenia-associated genetic loci. Nature (2014) 16.13
Cortical inhibitory neurons and schizophrenia. Nat Rev Neurosci (2005) 11.68
Developmental and regional expression in the rat brain and functional properties of four NMDA receptors. Neuron (1994) 11.44
Glutamate receptor ion channels: structure, regulation, and function. Pharmacol Rev (2010) 11.25
Antidepressant effects of ketamine in depressed patients. Biol Psychiatry (2000) 10.91
Regulation of NMDA receptor trafficking by amyloid-beta. Nat Neurosci (2005) 9.17
Glycine potentiates the NMDA response in cultured mouse brain neurons. Nature (1987) 8.89
Natural oligomers of the Alzheimer amyloid-beta protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway. J Neurosci (2007) 8.27
1,026 experimental treatments in acute stroke. Ann Neurol (2006) 7.23
NMDA receptor subunits: diversity, development and disease. Curr Opin Neurobiol (2001) 6.96
NMDA receptor trafficking in synaptic plasticity and neuropsychiatric disorders. Nat Rev Neurosci (2007) 6.26
Role of NMDA receptor subtypes in governing the direction of hippocampal synaptic plasticity. Science (2004) 5.76
Glutamate receptor dysfunction and schizophrenia. Arch Gen Psychiatry (1995) 5.59
Synaptic versus extrasynaptic NMDA receptor signalling: implications for neurodegenerative disorders. Nat Rev Neurosci (2010) 5.27
NMDA receptor subunit diversity: impact on receptor properties, synaptic plasticity and disease. Nat Rev Neurosci (2013) 4.35
Postnatal NMDA receptor ablation in corticolimbic interneurons confers schizophrenia-like phenotypes. Nat Neurosci (2009) 4.32
D-serine is an endogenous ligand for the glycine site of the N-methyl-D-aspartate receptor. Proc Natl Acad Sci U S A (2000) 3.71
NMDA receptor subunits have differential roles in mediating excitotoxic neuronal death both in vitro and in vivo. J Neurosci (2007) 3.44
Long-term depression in the CNS. Nat Rev Neurosci (2010) 3.27
Synaptic and extrasynaptic NMDA receptors are gated by different endogenous coagonists. Cell (2012) 3.22
NMDAR inhibition-independent antidepressant actions of ketamine metabolites. Nature (2016) 3.18
The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments. Am J Psychiatry (2007) 2.89
Allosteric binding sites on cell-surface receptors: novel targets for drug discovery. Nat Rev Drug Discov (2002) 2.85
Cognitive dysfunction in schizophrenia: convergence of gamma-aminobutyric acid and glutamate alterations. Arch Neurol (2006) 2.73
Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression. Biol Psychiatry (2012) 2.69
The glycinergic inhibitory synapse. Cell Mol Life Sci (2001) 2.50
Density of glutamic acid decarboxylase 67 messenger RNA-containing neurons that express the N-methyl-D-aspartate receptor subunit NR2A in the anterior cingulate cortex in schizophrenia and bipolar disorder. Arch Gen Psychiatry (2004) 2.37
Add-on treatment of benzoate for schizophrenia: a randomized, double-blind, placebo-controlled trial of D-amino acid oxidase inhibitor. JAMA Psychiatry (2013) 2.24
Crystal structure of a heterotetrameric NMDA receptor ion channel. Science (2014) 2.22
A critical role for NMDA receptors in parvalbumin interneurons for gamma rhythm induction and behavior. Mol Psychiatry (2011) 2.20
Control of NMDA receptor function by the NR2 subunit amino-terminal domain. J Neurosci (2009) 2.19
Submillisecond AMPA receptor-mediated signaling at a principal neuron-interneuron synapse. Neuron (1997) 2.14
The impact of NMDA receptor hypofunction on GABAergic neurons in the pathophysiology of schizophrenia. Schizophr Res (2015) 2.14
NMDA receptors in clinical neurology: excitatory times ahead. Lancet Neurol (2008) 2.13
Sarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study. Arch Gen Psychiatry (2005) 2.08
Triheteromeric NMDA receptors at hippocampal synapses. J Neurosci (2013) 2.01
Modulation of triheteromeric NMDA receptors by N-terminal domain ligands. Neuron (2005) 2.01
NMDA receptor structures reveal subunit arrangement and pore architecture. Nature (2014) 1.99
NMDA di-heteromeric receptor populations and associated proteins in rat hippocampus. J Neurosci (2007) 1.95
Functional comparison of D-serine and glycine in rodents: the effect on cloned NMDA receptors and the extracellular concentration. J Neurochem (1995) 1.79
Differential roles of NR2A and NR2B-containing NMDA receptors in LTP and LTD in the CA1 region of two-week old rat hippocampus. Neuropharmacology (2006) 1.77
Modulation of N-methyl-D-aspartic acid receptor desensitization by glycine in mouse cultured hippocampal neurones. J Physiol (1990) 1.77
Cloning and expression of a glycine transporter reveal colocalization with NMDA receptors. Neuron (1992) 1.75
Sarcosine (N-methylglycine) treatment for acute schizophrenia: a randomized, double-blind study. Biol Psychiatry (2007) 1.73
Glutamate-based therapeutic approaches: clinical trials with NMDA antagonists. Curr Opin Pharmacol (2005) 1.71
D-amino acids in the brain: D-serine in neurotransmission and neurodegeneration. FEBS J (2008) 1.63
Triheteromeric NR1/NR2A/NR2B receptors constitute the major N-methyl-D-aspartate receptor population in adult hippocampal synapses. J Biol Chem (2010) 1.63
Inhibition of glycine transporter-I as a novel mechanism for the treatment of depression. Biol Psychiatry (2013) 1.59
GABAergic interneuron origin of schizophrenia pathophysiology. Neuropharmacology (2011) 1.55
Excitotoxicity: perspectives based on N-methyl-D-aspartate receptor subtypes. J Pharmacol Exp Ther (2002) 1.52
Acute but not chronic activation of the NMDA-coupled glycine receptor with D-cycloserine facilitates learning and retention. Eur J Pharmacol (1994) 1.47
Strategies to enhance N-methyl-D-aspartate receptor-mediated neurotransmission in schizophrenia, a critical review and meta-analysis. Curr Pharm Des (2010) 1.44
Cell type-specific development of NMDA receptors in the interneurons of rat prefrontal cortex. Neuropsychopharmacology (2009) 1.43
Ketamine and rapid-acting antidepressants: a window into a new neurobiology for mood disorder therapeutics. Annu Rev Med (2014) 1.39
A subunit-selective potentiator of NR2C- and NR2D-containing NMDA receptors. Nat Commun (2010) 1.38
Glycine tranporter-1 blockade potentiates NMDA-mediated responses in rat prefrontal cortical neurons in vitro and in vivo. J Neurophysiol (2003) 1.38
Localization of the GLYT1 glycine transporter at glutamatergic synapses in the rat brain. Cereb Cortex (2005) 1.37
Differential roles of NMDA receptor subtypes in ischemic neuronal cell death and ischemic tolerance. Stroke (2008) 1.32
Distinct functional and pharmacological properties of Triheteromeric GluN1/GluN2A/GluN2B NMDA receptors. Neuron (2014) 1.28
Glycine transporters as novel therapeutic targets in schizophrenia, alcohol dependence and pain. Nat Rev Drug Discov (2013) 1.27
Interactions between the glycine and glutamate binding sites of the NMDA receptor. J Neurosci (1993) 1.27
Synaptic plasticity and depression: new insights from stress and rapid-acting antidepressants. Nat Med (2016) 1.26
D-serine is a key determinant of glutamate toxicity in amyotrophic lateral sclerosis. EMBO J (2007) 1.26
The NMDA receptor as a target for cognitive enhancement. Neuropharmacology (2012) 1.24
A novel family of negative and positive allosteric modulators of NMDA receptors. J Pharmacol Exp Ther (2010) 1.22
Control of feedforward dendritic inhibition by NMDA receptor-dependent spike timing in hippocampal interneurons. J Neurosci (2002) 1.22
Postsynaptic glutamate receptors and integrative properties of fast-spiking interneurons in the rat neocortex. J Neurophysiol (1999) 1.20
Large variability in synaptic N-methyl-D-aspartate receptor density on interneurons and a comparison with pyramidal-cell spines in the rat hippocampus. Neuroscience (2003) 1.19
The involvement of the NMDA receptor D-serine/glycine site in the pathophysiology and treatment of schizophrenia. Neurosci Biobehav Rev (2009) 1.18
NMDA receptors, cognition and schizophrenia--testing the validity of the NMDA receptor hypofunction hypothesis. Neuropharmacology (2011) 1.16
Stroke intervention pathways: NMDA receptors and beyond. Trends Mol Med (2011) 1.16
Allosteric modulation of NMDA receptor via elevation of brain glycine and D-serine: the therapeutic potentials for schizophrenia. Pharmacol Ther (2008) 1.13
Glutamatergic synaptic dysregulation in schizophrenia: therapeutic implications. Handb Exp Pharmacol (2012) 1.12
The NMDA receptor 'glycine modulatory site' in schizophrenia: D-serine, glycine, and beyond. Curr Opin Pharmacol (2014) 1.11
Glycine and D-serine increase the affinity of N-methyl-D-aspartate sensitive glutamate binding sites in rat brain synaptic membranes. Neuropharmacology (1988) 1.11
A randomized, double-blind, placebo-controlled comparison study of sarcosine (N-methylglycine) and D-serine add-on treatment for schizophrenia. Int J Neuropsychopharmacol (2009) 1.08
Biochemical and molecular studies of NMDA receptor subunits NR1/2A/2B in hippocampal subregions throughout progression of Alzheimer's disease pathology. Neurobiol Dis (2004) 1.08
Opposing roles of synaptic and extrasynaptic NMDA receptor signaling in cocultured striatal and cortical neurons. J Neurosci (2012) 1.05
Positive Allosteric Modulators of GluN2A-Containing NMDARs with Distinct Modes of Action and Impacts on Circuit Function. Neuron (2016) 1.04
NR2A-/- mice lack long-term potentiation but retain NMDA receptor and L-type Ca2+ channel-dependent long-term depression in the juvenile superior colliculus. J Neurosci (2007) 1.03
High-dose glycine added to olanzapine and risperidone for the treatment of schizophrenia. Biol Psychiatry (2004) 1.02
Pharmacological modulation of NMDA receptor activity and the advent of negative and positive allosteric modulators. Neurochem Int (2012) 1.02
D-serine for the treatment of negative symptoms in individuals at clinical high risk of schizophrenia: a pilot, double-blind, placebo-controlled, randomised parallel group mechanistic proof-of-concept trial. Lancet Psychiatry (2015) 1.01
NMDA receptors in nervous system diseases. Neuropharmacology (2013) 1.00
Randomized proof of concept trial of GLYX-13, an N-methyl-D-aspartate receptor glycine site partial agonist, in major depressive disorder nonresponsive to a previous antidepressant agent. J Psychiatr Pract (2015) 1.00
The effects of a subanesthetic dose of ketamine on verbal memory in normal volunteers. Psychopharmacology (Berl) (2005) 0.99
Allosteric modulators of NMDA receptors: multiple sites and mechanisms. Curr Opin Pharmacol (2014) 0.94
Discovery of GluN2A-Selective NMDA Receptor Positive Allosteric Modulators (PAMs): Tuning Deactivation Kinetics via Structure-Based Design. J Med Chem (2016) 0.93
D-cycloserine in Schizophrenia: New Strategies for Improving Clinical Outcomes by Enhancing Plasticity. Curr Neuropharmacol (2017) 0.90
Active release of glycine or D-serine saturates the glycine site of NMDA receptors at the cerebellar mossy fibre to granule cell synapse. Eur J Neurosci (2003) 0.90
D-Serine-induced nephrotoxicity: a HPLC-TOF/MS-based metabonomics approach. Toxicology (2005) 0.88
GluN2D-containing NMDA receptors-mediate synaptic currents in hippocampal interneurons and pyramidal cells in juvenile mice. Front Cell Neurosci (2015) 0.86
Enhanced hippocampal neuronal excitability and LTP persistence associated with reduced behavioral flexibility in the maternal immune activation model of schizophrenia. Hippocampus (2013) 0.85
Rapastinel (GLYX-13) has therapeutic potential for the treatment of post-traumatic stress disorder: Characterization of a NMDA receptor-mediated metaplasticity process in the medial prefrontal cortex of rats. Behav Brain Res (2015) 0.84
Glycine and D: -serine, but not D: -cycloserine, attenuate prepulse inhibition deficits induced by NMDA receptor antagonist MK-801. Psychopharmacology (Berl) (2008) 0.83
Coumarin-3-carboxylic acid derivatives as potentiators and inhibitors of recombinant and native N-methyl-D-aspartate receptors. Neurochem Int (2012) 0.82
Impaired attention and synaptic senescence of the prefrontal cortex involves redox regulation of NMDA receptors. J Neurosci (2015) 0.82
The long-lasting antidepressant effects of rapastinel (GLYX-13) are associated with a metaplasticity process in the medial prefrontal cortex and hippocampus. Neuroscience (2015) 0.82
The Functional and Molecular Properties, Physiological Functions, and Pathophysiological Roles of GluN2A in the Central Nervous System. Mol Neurobiol (2016) 0.80